Pamiparib

Generic Name
Pamiparib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C16H15FN4O
CAS Number
1446261-44-4
Unique Ingredient Identifier
8375F9S90C
Background

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).

Indication

用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。

Associated Conditions
-
Associated Therapies
-

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

First Posted Date
2017-11-07
Last Posted Date
2024-02-22
Lead Sponsor
BeiGene
Target Recruit Count
128
Registration Number
NCT03333915
Locations
🇨🇳

Anhui Provincial Cancer Hospital, Hefei, Anhui, China

🇨🇳

Jilin Cancer Hospital, Changchun, Jilin, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 23 locations

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

First Posted Date
2017-05-12
Last Posted Date
2022-05-31
Lead Sponsor
BeiGene USA, Inc.
Target Recruit Count
116
Registration Number
NCT03150862
Locations
🇺🇸

UCLA Neuro-Oncology, Los Angeles, California, United States

🇺🇸

Sarah Cannon Research Institute at Health One, Denver, Colorado, United States

🇺🇸

Washington University, Saint Louis, Missouri, United States

and more 17 locations

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

First Posted Date
2017-05-12
Last Posted Date
2024-12-20
Lead Sponsor
BeiGene
Target Recruit Count
139
Registration Number
NCT03150810
Locations
🇺🇸

Start Midwest, Grand Rapids, Michigan, United States

🇺🇸

Washington University in St Louis, Saint Louis, Missouri, United States

🇺🇸

Montefiore Medical Park At Eastchester Einstein Campus, Bronx, New York, United States

and more 19 locations

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-01-21
Last Posted Date
2021-12-06
Lead Sponsor
BeiGene
Target Recruit Count
229
Registration Number
NCT02660034
Locations
🇦🇺

Prince of Wales, Randwick, New South Wales, Australia

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇬🇧

Sarah Cannon Research Institute, London, United Kingdom

and more 24 locations
© Copyright 2024. All Rights Reserved by MedPath